These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 2692201)

  • 1. Pathomechanisms of atherosclerosis beneficially affected by prostaglandin E1 (PGE1)--an update.
    Sinzinger H; Virgolini I; Fitscha P
    Vasa Suppl; 1989; 28():6-13. PubMed ID: 2692201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacotherapy of arteriosclerosis and its complications. Effect of ACE inhibitors and HMG-CoA-reductase inhibitors].
    Tschudi MR; Noll G; Lüscher TP
    Schweiz Med Wochenschr; 1997 Apr; 127(15):636-49. PubMed ID: 9198890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of leukocyte adherence and transendothelial migration in cultured human liver vascular endothelial cells by prostaglandin E1.
    Lou J; Bühler L; Deng S; Mentha G; Montesano R; Grau GE; Morel P
    Hepatology; 1998 Mar; 27(3):822-8. PubMed ID: 9500713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eicosanoids in the local regulation of haemostasis.
    Sinzinger H; Wasinger T
    Z Kardiol; 1989; 78 Suppl 6():30-4. PubMed ID: 2515671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The pharmacology of 13,14-dihydro-PGE1 in comparison with PGE1].
    Braun M; Ney P; Hohlfeld T; Szymanski C; Bruch L; Schrör K
    Vasa Suppl; 1991; 33():337-8. PubMed ID: 1788747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacologic concepts for clinical use of prostaglandin E1].
    Schrör K
    Vasa Suppl; 1991; 33():335-6. PubMed ID: 1788746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostaglandin E1 decreases circulating endothelial cells.
    Sinzinger H; Fitscha P; Kritz H; Rogatti W; Grady JO
    Prostaglandins; 1996 Jan; 51(1):61-8. PubMed ID: 8900444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of endothelial progenitor cells by prostaglandin E1 via inhibition of apoptosis.
    Gensch C; Clever Y; Werner C; Hanhoun M; Böhm M; Laufs U
    J Mol Cell Cardiol; 2007 Mar; 42(3):670-7. PubMed ID: 17291526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimitotic actions of vasodilatory prostaglandins--clinical aspects.
    Sinzinger H; Fitscha P; Kritz H
    Agents Actions Suppl; 1997; 48():92-106. PubMed ID: 9177101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience.
    Porst H
    J Urol; 1996 Mar; 155(3):802-15. PubMed ID: 8583582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The endothelium in acute coronary syndromes.
    Noll G; Lüscher TF
    Eur Heart J; 1998 Apr; 19 Suppl C():C30-8. PubMed ID: 9597423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor.
    Mohacsi PJ; Tüller D; Hulliger B; Wijngaard PL
    J Heart Lung Transplant; 1997 May; 16(5):484-92. PubMed ID: 9171265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potentiation of alpha-naphthyl thiourea-induced lung injury by prostaglandin E1 and platelet depletion.
    Fantone JC; Kunkel RG; Kinnes DA
    Lab Invest; 1984 Jun; 50(6):703-10. PubMed ID: 6233454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pathogenesis of atherosclerosis: atherogenesis and inflammation.
    Munro JM; Cotran RS
    Lab Invest; 1988 Mar; 58(3):249-61. PubMed ID: 3279259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired responsiveness of platelets from patients with stable angina pectoris to antiaggregating and cyclicAMP-elevating effects of prostaglandin E1.
    Chirkov YY; Chirkova LP; Sage RE; Horowitz JD
    J Cardiovasc Pharmacol; 1995 Jun; 25(6):961-6. PubMed ID: 7564342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction?
    Comparato C; Altana C; Bellosta S; Baetta R; Paoletti R; Corsini A
    Nutr Metab Cardiovasc Dis; 2001 Oct; 11(5):328-43. PubMed ID: 11887430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelets and chemokines in atherosclerosis: partners in crime.
    Weber C
    Circ Res; 2005 Apr; 96(6):612-6. PubMed ID: 15802619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PGE1-induced arterial thromboresistance is a vascular property as identified by cross-perfusion technique.
    Sinzinger H; Neumann I; O'Grady J; Rogatti W; Peskar BA
    Prostaglandins Leukot Essent Fatty Acids; 1997 Apr; 56(4):325-30. PubMed ID: 9150379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemodynamic and neurohumoral effects of long-term prostaglandin E1 infusions in outpatients with severe congestive heart failure.
    Hülsmann M; Stanek B; Frey B; Berger R; Rödler S; Siegel A; Hartter E; Schuller M; Ogris E; Pacher R
    J Heart Lung Transplant; 1997 May; 16(5):556-62. PubMed ID: 9171275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Migraine: possible role of platelet insensitivity to prostaglandin E1 (PGE1).
    Cerneca F; de Luyk S; Radillo O; Simeone R; Mangiarotti M
    Funct Neurol; 1993; 8(6):403-8. PubMed ID: 8150318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.